Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD
April 10, 2014 at 16:09 PM EDT
Theravance, Inc. (NASDAQ: THRX) announced the initiation of the dose-ranging Phase 2b Study 0117 with TD-4208 as a nebulized aqueous ...